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Abstract
Background: Avid renal sodium and water retention among other mechanisms produce ascites in patients with
cirrhosis. The main guidelines recommend sodium intake reduction in order to counteract this complication.
However, some randomized controlled trials have suggested a lack of benefit with a sodium-restricted over an
unrestricted diet, and even an increase in ascites and renal complications has been reported. There are no
systematic reviews addressing this question.
Methods: A systematic review protocol has been designed and will be reported in line with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). We will search for randomized controlled trials
evaluating a salt-restricted versus unrestricted regime in patients with cirrhosis and ascites in EMBASE, MEDLINE, and
the Cochrane Central Register of Controlled Trials. We will also try to identify literature by reviewing reference list of
included studies and relevant reviews, screening main conference proceedings, and searching for unpublished and
ongoing trials in the World Health Organization (WHO) International Clinical Trials Registry Platform.
Two researchers will independently undertake selection of studies, data extraction, and assessment of the quality of
included studies.
We will estimate pooled risk ratios for dichotomous data and the mean difference or standardized mean difference for
continuous outcomes. A random effect model will be used for meta-analyses. Data synthesis and other analyses will be
conducted using RevMan software. Ethics and dissemination: no ethics approval is considered necessary. Results of this
study will be disseminated via peer-reviewed publications and social networks
Discussion: Sodium restriction is a widely accepted coadjuvant therapy for ascites; however, this indication is based
primarily on expert recommendations. As far as we know, this will be the first systematic review assessing the effects of
a sodium-restricted diet for ascites in cirrhotic patients.
Our systematic review will aim to provide a high-quality synthesis of current evidence for patients and clinicians about
this question.
The main limitation might result from the reduced number and quality of primary studies available.
Systematic review registration:: PROSPERO CRD42015022161
Background
Hepatic cirrhosis represents the final stage of progressive
and irreversible liver fibrosis observed in chronic hepatic
disease. Liver architecture distortion determines portal
hypertension. Added neurohumoral changes produce
peripheral vasodilation, increased circulating volume,
and sinusoidal vasoconstriction. The exact mechanism
of peripheral vasodilatation is still unclear, but appar-
ently, it is due to an imbalance between vasoconstrictors
and vasodilators released as response to increased portal
vascular resistance [1]. Circulating volume is increased
primarily because of avid renal sodium and water reten-
tion due to relative hypovolemia sensed by the juxtaglo-
merular apparatus. Sodium and water reabsorption are
mediated by increased secretion of renin, angiotensin,
and aldosterone; an increased secretion of antidiuretic
hormone retains free water [2, 3].
Ascites occurs as a consequence of these factors, gen-
erating a wide range of problems that affect life
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expectancy starting with general disability, dyspnea, peri-
toneal infections, renal failure, and finally death [4].
Salt restriction appears as an obvious way to avoid so-
dium retention and water overload.
It is usually posited that in order to avoid fluid retention,
oral sodium intake must be significantly reduced in order
to achieve a negative sodium balance. Salt restriction
would further decrease fluid accumulation by lowering
portal pressure through vascular volume depletion.
All major guidelines in this topic recommend salt re-
striction in these patients.
However, some authors warn that patients with cirrhotic
ascites have low blood sodium levels; therefore, the use of
diuretics and sodium restriction could decrease renal per-
fusion, resulting in further renal impairment and more as-
cites. Consequently, some randomized controlled studies
have suggested there would be no benefit, and even harm,
with a sodium-restricted over an unrestricted diet [5, 6].
There are no completed or ongoing systematic reviews
on this topic. Therefore, it is critical to provide a high-
quality synthesis of current evidence for patients and cli-
nicians about this question.
Objectives
The aim of this systematic review is to assess the effects
of a salt-restricted diet for patients with cirrhotic ascites.
Methods
A systematic review protocol has been designed and will
be reported in line with Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocols
(PRISMA-P) (Additional file 1).
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials.
Types of participants
We will include studies considering adult patients diag-
nosed with liver cirrhosis of any etiology with confirmed as-
cites. We will exclude studies of patients with comorbidities
that can mimic cirrhotic ascites such as heart and lung in-
sufficiency and patients with previous renal impairment.
Types of interventions
Treatment group: sodium-restricted diet
Control group: unrestricted
We will also include studies comparing diets with dif-
ferent amounts of sodium, if at least one arm can be
considered unrestricted. We will define unrestricted as
more than 250 mEq per day.
Types of outcomes measures
Primary outcomes
Overall mortality
Ascites improvement measured by any method
Secondary Outcomes
Sodium plasma levels
Markers of renal dysfunction
Hospitalization
Search methods for identification of studies
We will conduct sensitive electronic searches (with no
language or publication restrictions) in EMBASE, MEDLINE,
and the Cochrane Central Register of Controlled Trials.
The following strategy will be used to search MED-
LINE (PubMed) and adapted for other sources:
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]




#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 animals [mh] NOT humans [mh]





#16 salt[ti] OR sodium[ti]
#17 (restrict* OR low OR reduc* OR intak* OR added
OR diet OR consum* OR excess* OR increas* or high)
AND (salt OR sodium)
# 18 #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 "Liver Cirrhosis"[Mesh]
#20 (hepatic or liver) and (fibrosis or cirrho* OR ascit*)
#21 #19 OR #20
#21 #11 AND #18 AND #21
Additionally, we will do the following:
– Review clinical practice guidelines and relevant
reviews for potentially eligible studies
– Screen the list of references of relevant reviews and
included studies identified
– Manually review proceedings of major conferences
in the area
– Search for ongoing studies in the World Health
Organization (WHO) International Clinical Trials
Registry Platform (ICTRP)
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Selection of studies, data extraction, and
management
Deduplicated records will be uploaded to Covidence
Software (www.covidence.org).
Two reviewers will independently screen the titles and
abstracts of all records. The full-text paper of all poten-
tially eligible studies will be obtained for a detailed
evaluation and assessed by the same review authors in
order to decide on fulfillment of our inclusion criteria.
The same reviewers will extract data using an ad
hoc piloted data extraction form. Disagreements will
be discussed by all reviewers and judged by an arbi-
ter. The following data will be extracted: (1) general
information of the study; (2) study characteristics
(study design, sample size, number of arms, method-
ology of randomization and allocation concealment,
blinding, settings); (3) participants (age, gender, ethni-
city, method of diagnosis, etiology of cirrhosis, sever-
ity of cirrhosis or ascites); (4) interventions and
controls (type of interventions, characteristics of salt-
restricted diet, duration of treatment or follow-up);
(5) outcomes (type of outcome, definition of outcome,
time point of assessment); and (6) results.
Assessment of risk of bias in included studies
Two review authors will independently extract data in
pre-designed data extraction and validity assessment
forms. A third review author will act as an arbiter in
case of disagreement. The methodological quality will be
assessed with the Cochrane Collaboration’s tool for
assessing risk of bias (Cochrane Handbook (V.5.1.0)), by
the following criteria: (1) randomization; (2) allocation
concealment; (3) blinding; (4) data integrity; (5) selective
reporting; and (6) other bias, such as trial design, base-
line similarity of groups, and early cessation of treat-
ment. For all of the studies, the assessment should
follow the above six criteria and be categorized as low,
unclear, or high risk of bias.
Measures of treatment effect
Dichotomous data will be determined by using a risk ra-
tio (RR) with 95 % confidence interval (CI), whereas
continuous outcomes will be analyzed using mean differ-
ences (with 95 % CI) or standardized mean differences
(95 % CI) if different measurement scales are used.
Assessment of heterogeneity
We will assess heterogeneity quantitatively with a formal
statistical test (Q statistic) and the I2 statistic. Statistically
significant heterogeneity will be defined as at least one
positive test (either P < 0.10 using the Mantel-Haenszel
chi2 test or >50 % using the I2 statistic).
Data synthesis
If possible, all trials will be combined in a meta-analysis
comparing salt-restricted diet versus unrestricted diets.
A random effects model will be used for all the analyses.
Separate meta-analyses will be presented for specific
populations or interventions if statistically significant
heterogeneity is explained by some of these or if a con-
vincing subgroup effect is found.
We will perform statistical analysis in accordance with
the guidelines for statistical analysis developed by The
Cochrane Collaboration, using the statistical software
RevMan 5.3.
Subgroup analysis and investigation of
heterogeneity




We will perform sensitivity analyses to address the
impact of studies with higher or lower bias risk.
Assessment of reporting bias
We will investigate the publication bias visually with the
use of funnel plots. We will base evidence of asymmetry
on P < 0.10 and present intercepts with 90 % CIs. Out-
come reporting bias will be evaluated through discrepan-
cies between the registered protocol and the final
publication. We will contact authors for more informa-
tion if we are not able to find the record of a study in
the trials registries.
Grading the certainty of evidence
We will judge the certainty of the evidence for all out-
comes using the Grading of Recommendations Assess-
ment, Development, and Evaluation working group
methodology [7].
Discussion
This systematic review will synthesize scientific evidence
for the effect of diet restriction sodium on ascites.
As far as we know, this will be the first systematic re-
view to assess the effectiveness and safety of sodium-
restricted diet for ascites in cirrhotic patients. It aims to
provide a high-quality synthesis of the current evidence
for patients and clinicians about this question.
The main limitation might result from the reduced
number and quality of primary studies available.
Another limitation might arise from the lack of
standardization in the definition of ascites and treat-
ment success or failure. The findings from this sys-
tematic review will be valuable in the decision-making
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process about the effect of sodium-restricted diet as
therapy for ascites.
Additional files
Additional file 1: Corresponds to PRISMA-P checklist. This checklist
covers reporting standards for protocol of systematic reviews. The file
mentions if these have been covered by the protocol, and where in the
text these items are covered.
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